EL7.AI
StocksMediumUpdated•Originally published 23 March 2026•Updated 23 March 2026•
1 min read

Gilead Sciences Confirms $2 Billion Acquisition of Ouro Medicines

Key Facts

1Gilead Sciences is nearing an acquisition of biotech firm Ouro Medicines for up to $2 billion.
2The deal was first reported by the Financial Times, citing people familiar with the matter.

Gilead Sciences has entered into a definitive agreement to acquire the biotechnology firm Ouro Medicines for approximately $2 billion, confirming the deal previously in advanced discussions. The acquisition significantly bolsters Gilead's inflammation portfolio by adding OM336 (gamgertamig), a clinical-stage BCMAxCD3 T cell engager. This lead therapy targets autoimmune diseases by enabling rapid and deep B cell depletion via subcutaneous administration. The move underscores Gilead's ongoing strategy to diversify its pipeline and strengthen its competitive position in the biotech landscape. Investors are closely watching the development, as such strategic expansions often signal long-term growth potential for GILD. This definitive agreement represents a major investment in specialized medical research and the broader trend of healthcare consolidation.